Radiopharm Theranostics (RDPTF) Share-based Compensation (2023 - 2025)
Radiopharm Theranostics' (RDPTF) quarterly Share-based Compensation came in at -$1.9 million in Q2 2025, up 28.21% year-over-year from -$1.5 million in Q2 2024, and up 28.21% quarter-over-quarter from -$2.6 million in Q2 2024.
Powered by 
Analysis
Radiopharm Theranostics (RDPTF) Share-based Compensation (2023 - 2025) Analysis & Trends
Radiopharm Theranostics (RDPTF) has reported Share-based Compensation for 3 consecutive years, with -$1.9 million the latest figure, recorded in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.05 Bn | 198.06 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 181.76 Bn | 178.58 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.46 Bn | 124.61 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 82.66 Bn | 74.67 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 61.56 Bn | 56.37 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.56 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.46 Bn | 30.17 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 30.15 Bn | 30.15 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Radiopharm Theranostics | 23.65 Mn | 23.60 Mn | -92,644.38 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -1.90 Mn |
| Jun 30, 2024 | -2.64 Mn |
| Jun 30, 2023 | -3.04 Mn |